BioMarin Pharmaceutical’s (BMRN) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note released on Tuesday morning, Marketbeat.com reports. The firm currently has a $60.00 price target on the biotechnology company’s stock.

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on BioMarin Pharmaceutical from $86.00 to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, October 20th. Oppenheimer lowered their target price on BioMarin Pharmaceutical from $97.00 to $94.00 and set an “outperform” rating for the company in a research note on Tuesday. UBS Group assumed coverage on BioMarin Pharmaceutical in a research note on Thursday, October 15th. They set a “buy” rating and a $88.00 target price for the company. Finally, Canaccord Genuity Group increased their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.91.

BioMarin Pharmaceutical Trading Down 1.7%

NASDAQ BMRN opened at $56.15 on Tuesday. The firm has a 50 day simple moving average of $59.87 and a 200-day simple moving average of $58.47. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.44. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of 32.10, a PEG ratio of 0.68 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.28. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. The firm’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.12 EPS. Equities research analysts anticipate that BioMarin Pharmaceutical will post 2.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System grew its position in shares of BioMarin Pharmaceutical by 15.0% during the third quarter. Maryland State Retirement & Pension System now owns 11,002 shares of the biotechnology company’s stock worth $660,000 after acquiring an additional 1,431 shares during the last quarter. Lisanti Capital Growth LLC acquired a new position in shares of BioMarin Pharmaceutical during the third quarter worth about $6,176,000. New York Life Investment Management LLC raised its stake in shares of BioMarin Pharmaceutical by 14.4% during the 3rd quarter. New York Life Investment Management LLC now owns 27,564 shares of the biotechnology company’s stock worth $1,654,000 after buying an additional 3,460 shares in the last quarter. M&G PLC raised its position in BioMarin Pharmaceutical by 1.2% in the third quarter. M&G PLC now owns 218,723 shares of the biotechnology company’s stock worth $13,123,000 after acquiring an additional 2,627 shares in the last quarter. Finally, AlphaCore Capital LLC increased its holdings in shares of BioMarin Pharmaceutical by 73.9% in the 3rd quarter. AlphaCore Capital LLC now owns 6,367 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 2,706 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported Q3 revenue of $1.02 billion, up 32% year over year, and EPS of $0.23 versus analysts’ expected loss of $0.05. Revenue was in line with consensus, while earnings beat expectations. BioMarin Q3 2026 earnings call highlights
• Positive Sentiment: An analyst sees a more attractive risk-reward profile ahead of three FDA decisions. Potential expansion of Voxzogo into hypochondroplasia and revenue from the Amicus acquisition could support growth, though the acquisition’s debt burden remains a consideration. BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
• Neutral Sentiment: JPMorgan lowered its price target to $86 from $87 but maintained an Overweight rating. HC Wainwright also reaffirmed its Neutral rating. JPMorgan analyst rating HC Wainwright rating
• Neutral Sentiment: Management plans to present at three November investor conferences; the announcement did not include new financial guidance. BioMarin investor conferences announcement
• Negative Sentiment: Royal Bank of Canada and Morgan Stanley lowered their expectations for BMRN, contributing to selling pressure and a gap lower in the shares following an analyst downgrade. RBC lowers expectations Morgan Stanley lowers expectations Shares gap down following analyst downgrade

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.